H.C. Wainwright lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $1.50 from $5 and keeps a Buy rating on the shares following the Q3 report. The company reported “less than enthusiastic” Xolremdi uptake, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals Reports Positive Trial Results and Progress
- X4 Pharmaceuticals price target lowered to $4 from $5 at Stifel
- X4 Pharmaceuticals: Promising Phase 2 Trial Results
- X4 Pharmaceuticals reports Q3 EPS (18c), consensus (17c)
- X4 reports data from Phase 2 clinical trial evaluating mavorixafor